"Biota prepares path for next flu treatment Tuesday, 11 August 2009 | The Australian Financial Review | Nabila Ahmed
Biota chief executive Peter Cook is looking for a senior licensing partner to help market the company's next generation influenza treatment, laninamivir, in the Western world, after the drug was found to be safe and effective in final stage clinical trials in Asia."
it also says"Broker ABN Amro expected Biota to tie up a licensing agreement in the next six months.The broker said laninamivir represented $1.05 of its $2.26 valuation of the stock".
any thoughts?
BTA Price at posting:
$2.17 Sentiment: Hold Disclosure: Held
